Virax Biolabs Group Ltd (VRAX) Equity Average (2022 - 2025)

Virax Biolabs (VRAX) has 4 years of Equity Average data on file, last reported at $5.4 million in Q1 2025.

• In Q1 2025, Equity Average fell 22.84% year-over-year to $5.4 million; the TTM figure through Mar 2025 stood at $5.4 million (down 22.84% YoY), while the FY2025 annual figure was $5.4 million, down 22.84% from the prior year.
• Equity Average slipped to $5.4 million in Q1 2025, from $7.0 million in the prior quarter.
• Across five years, Equity Average topped out at $7.0 million in Q1 2024 and bottomed at -$1.0 million in Q1 2022.
• A 4-year average of $3.8 million and a median of $4.6 million in 2023 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2023 — Equity Average surged 479.95% — and 2025, when it slipped 22.84%.
• Year by year, Equity Average stood at -$1.0 million in 2022, then surged by 479.95% to $3.9 million in 2023, then jumped by 82.2% to $7.0 million in 2024, then dropped by 22.84% to $5.4 million in 2025.
• The last three Equity Average figures came in at $5.4 million (Q1 2025), $7.0 million (Q1 2024), and $3.9 million (Q1 2023), per Business Quant data.

Peer Comparison